Lumiracoxib

Drugs of Today

Volumn 43, Issue 3, 2007, Pages 137-147

  Buvanendran, Asokumar ^a   Barkin, Robert ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 5 CARBOXY LUMIRACOXIB; 4 HYDROXY LUMIRACOXIB; 5 CARBOXY LUMIRACOXIB; ACETYLSALICYLIC ACID; ALUMINUM HYDROXIDE; ANTACID AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DRUG METABOLITE; ETORICOXIB; GLUCURONIDE; IBUPROFEN; LOCAL ANESTHETIC AGENT; LUMIRACOXIB; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROSTACYCLIN; ROFECOXIB; UNCLASSIFIED DRUG; WARFARIN;

AGE DISTRIBUTION; ALLERGIC REACTION; ANALGESIA; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; ASTHMA; BLOOD PRESSURE; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC PAIN; CHRONIC SINUSITIS; CLINICAL TRIAL; COLORECTAL ADENOMA; CONTROLLED CLINICAL TRIAL; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DYSMENORRHEA; EDEMA; GASTROINTESTINAL EROSION; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; HEADACHE; HEART INFARCTION; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS; NEPHROTOXICITY; NOSE POLYP; OSTEOARTHRITIS; PAIN; POSTOPERATIVE PAIN; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH ULCER; STROKE; SYSTEMATIC REVIEW; TENSION HEADACHE; THROMBOEMBOLISM; THROMBOSIS; TOOTH PAIN; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DRUG INTERACTIONS; HUMANS;

EID: 34247493764     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.3.1062673     Document Type: Review

References (61)

1. Flowers, R., Moncada, S., Vane, J. Analgesic-anti-pyretics and anti-inflammatory agents: Drugs employed in the treatment of gout. In: Gilman, A., Goodman, L., Rall, T. et al. The Pharmacological Basis of Therapeutics (7 Ed.). Macmillan, New York 1985.
2. Von Euler, U.S. On the specific vasodilating and plain muscle stimulating substance from accessory genital glands in man and certain animals (prostaglandin and vestiglandin). J Physiol 1937, 88: 213-34.
3. Samad, T.A., Sapirstein, A., Woolf, C.J. Prostanoids and pain: Unraveling mechanisms and revealing therapeutic targets. Trends Mol Med 2002, 8: 390-6.
4. Cashman, J., McAnulty, G. Nonsteroidal anti-inflammatory drugs in perisurgical pain management: Mechanisms of action and rationale for optimum use. Drugs 1995, 49: 51-70.
5. Ferreira, S.H. Prostaglandins, aspirin-like drugs and analgesia. Nature 1972, 240: 200-3.
6. Giuliano, F., Warner, T.D. Origins of prostaglandins E2: Involvement of cyclooxygenase (COX)-1 and COX-2 in human and rat systems. J Pharmacol Therp 2002, 102: 1001-6.
7. Higgs, G.A. Arachidonic acid metabolism, pain and hyperalgesia: The mode of action of non-steroid mild analgesics. Br J Pharmacol 1980, 10; 233-5S.
8. Dray, A., Bevan, S. Inflammation and hyperalgesia: The team effort. Trends Pharm Sci 1993, 14: 287-62.
9. O'Banion, M.K., Sadowski, H.B., Winn, V. et al. A serum and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991, 266: 23261-7.
10. Smith, W.L., DeWitt, D.L., Garavito, R.M. et al. Cyclooxygenases: Structural, cellular biology. Annu Rev Biochem 2000, 69: 145-82.
11. Everts, B., Wahrborg, P., Hedner, T. et al. COX-2 specific inhibitors - the emergence of a new class of analgesic and anti-inflammatory drugs. Clin Rheumatol 2000, 19: 331-43.
12. Kraemer, S.A., Meade, E.A., DeWitte, D.L. Prostaglandin endoperoxide synthase gene structure: Identification of the transcriptional start site and 5′ flanking regulatory sequences. Arch Biochem Biophys 1992, 293: 391-400.
13. Chun, K.S., Surh, Y.J. Signal transduction pathways regulating cyclooxygenase-2 expression: Potential molecular targets for chemoprevention. Biochemical pharmacology 2004, 68: 1089-100.
14. O'Banion, M.K. Cyclooxygenase-2: Molecular biology, pharmacology and neurobiology. Crit Rev Neurobiol 1999, 13: 45-82.
15. Yaksh, T.L., Dirig, D.M., Conway, C.M. et al. The acute antihyperalgesic action of non-steroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci 2001, 21: 5847-53.
16. Vane, J.R. The mode of action of aspirin and similar compounds. J Allergy Clin Immunol 1976, 58: 691-712.
17. Kroin, J.S., Buvanendran, A., McCarthy, R.J. et al. Cyclooyxgenase-2 (COX-2) inhibitor potentiates morphine antinociception at the spinal level in a post-operative pain model. Reg Anesth Pain Med 2002, 27: 451-5.
18. Dai, Y.Q., Jin, D.Z., Zhu, X.Z. et al. Triptolide inhibits COX-2 expression via NF-kappa B pathway in astrocytes. Neurosci 2006, 55: 154-60.
19. Samad, T.A., Moore, K.A., Sapirstein, A. et al. Interleukin-1beta mediated induction of COX-2 in the central nervous system contributes to inflammatory pain hypersensitivity. Nature 2001, 410: 471-5.
20. 2 and interleukins in the central nervous system and peripheral tissue during and after surgery in humans. Anesthesiology 2006, 104: 403-10.
21. Kroin, J.S., Ling, Z.D., Buvanendran, A. et al. Upregulation of spinal cyclooxygenase-2 in rats after surgical incision. Anesthesiology 2004, 100: 364-9.
22. Reuben, S.S., Buvanendran, A., Kroin, J.S. et al. Postoperative modulation of central nervous system prostaglandins E2 by cyclooxygenase inhibitors after vascular surgery. Anesthesiology 2006, 104: 411-6.
23. Dembo, G., Park, S.B., Kharasch, E.D. Central nervous system concentration of cyclooxygenase-2 inhibitors in humans. Anesthesiology 2005, 102: 409-15.
24. Buvanendran, A., Kroin, J.S., Tuman, K.J. et al. Cerebrospinal fluid and plasma pharmacokinetics of the cyclooxygenase 2 inhibitor rofecoxib in humans: Single and multiple oral drug administration. Anesth Analg 2005, 100: 1320-4.
25. Lyseng-Williamson, K.A., Curran, M.P. Lumiracoxib. Drugs 2004, 64: 2237-46.
26. Scott, G., Rordorf, C., Blood, P. et al. Steady state pharmacodynamics of COX 189 in healthy subjects. Ann Rheum Dis 2002, 61 (Suppl. 1): 244.
27. Wilding, I.R., Connor, A.L., Carpenter, P. et al. Assessment of lumiracoxib bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy. Pharm Res 2004, 21: 443-6.
28. Mysler, E. Lumiracoxib: A new selective COX-2 inhibitor. Int J Clin Pract 2004, 58: 606-11.
29. Scott, G., Rordorf, C., Reynolds, C. et al. Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet 2004, 43: 467-78.
30. Capone, M.L., Tacconelli, S., Di Frabcesco, L. et al. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 2007, 82: 85-94.
31. Esser, R. 2005, Bery, C., Du, Z. et al. Preclinical pharmacology of lumiracoxib: A novel selective inhibitor of cyclooxygenase-2. Br J Pharmacology 2005, 144: 538-50.
32. Mangold, J.B., Gu, H., Rodriguez, L.C. et al. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab Dispos 2004, 32: 566-71.
33. Rordorf, C.M., Choi, L., Marshall, P., Mangold, J.B. Clinical pharmacology of lumiracoxib: A selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2005, 44: 1247-66.
34. Kalbag, J., Yeh, C.-M., Milosavljev, S. et al. No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor. Pharmacol Res 2004, 50: 181-6.
35. Schnitzer, T., Burmester, G.R., Mysler, E. et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: Randomized controlled trial. Lancet 2004, 364: 665-74.
36. Sheldon, E., Beaulieu, A., Paster, Z. et al. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: A 13-week, randomized, double-blind comparison with celecoxib and placebo. Clin Ther 2005, 27: 64-77.
37. Hawkey, C.C., Svoboda, P., Fiedorowicz-Fabrycy, I.F. et al. Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritis. J Rheumatol 2004, 31: 1804-10.
38. Schnitzer, T., Burmester, G.R., Mysler, E. et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: Randomized controlled trial. Lancet 2004, 364: 675-84.
39. Matchaba, P., Gitton, X., Krammer, G. et al. Cardiovascular safety of lumiracoxib: A meta-analysis of all randomized controlled trials > 1 week and up to 1 year in duration of patients with osteoarthritis and rheumatorid arthritis. Clin Ther 2005, 27: 1196-24.
40. Bresalier, R.S., Sandler, R.S., Quan, H. et al.; Adenomatous Polyp Prevention on Vioxx (APPROVE) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352: 1092-102.
41. Bombardier, C., Laine, L., Reicin, A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343: 1520-8.
42. Solomon, S.D., McMurray, J.V., Pfeffer, M.A. et al.; Adenoma Prevention with Celecoxib (APC) Study investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352: 1071-80.
43. National Institute of Health. Use of non-steroidal anti-inflammatory drugs suspended in large Alzheimer's disease prevention trial. FDA meeting, December 20, 2004. Available at: http://www.nih.gov/news/pr/dec2004/od20.htm.
44. Couzin, J. Clinical trails. Halt of Celebrex study threatens drug's future and other trials. Science 2004, 306: 2170.
45. Heim, H.K., Broich, K. Selective COX-2 inhibitors and risk of thromboembolic events-regulatory aspects. Thromb Haemost 2006, 96: 423-32.
46. Grosser, T., Fries, S., Fitzgerald, G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 2006, 116: 4-15.
47. Farkouh, M., Kirshner, H., Harrington, R.A. et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: Randomized controlled trial. Lancet 2004, 364: 675-84.
48. Jermany, J., Branson, J., Schmouder, R. et al. Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose asprin in healthy subjects. J Clin Pharmacol 2005, 45: 1172-8.
49. Rordorf, C., Scott, G., Milosavlljev, et al. Steady state pharmacokinetics, pharmacodynamics, safety and tolerability of COX 189 in healthy subjects. Ann Rheum Dis 2002, 61 (Suppl. 1): 420.
50. Bonner, J., Branson, J., Milosavijev, S. et al. Co-administration of lumiracoxib and warfarin does not alter the pharmacokinetics profile of RorS warfarin. Ann Rheum Dis 2003, 62: 264 (Abst. FRI0225).
51. Zelenakas, K., Fricke, J.R., Jayawardene, S., Kellstein, D. Analgesic efficacy of single oral doses of lumiracoxib and ibuprofen in patients with postoperative dental pain. Int J Clin Pract 2004, 58: 251-6.
52. Kellstein, D., Ott, D., Jayawardene, S., Fricke, J. Analgesic efficacy of single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of postoperative dental pain. Int J Clin Pract 2004, 58: 244-50.
53. Bitner, M., Kattenhorn, J., Hatfield, C. et al. Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhea. Int J Clin Pract 2004, 58: 340-5
54. Packman, E., Packman, B., Thurston, H. et al. Lumiracoxib is effective in the treatment of episodic tension type headache. Headache 2005, 45: 1163-70.
55. Schnitzer, T.J., Beier, J., Geusens, P. et al. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip osteoarthritis: A phase II, four week multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004, 15: 549-57.
56. Fleischmann, R., Sheldon, E., Maldonado-Cocco, J. et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: A prospective, randomized, 13-week study versus placebo and celecoxib. Clin Rheumatol 2005, 25: 42-53.
57. Grifka, J.K., Zacher, J., Brown, J.P. et al. Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand. Clin Exp Rheumatol 2004, 22: 589-96.
58. Berenbaum, F., Grifka, J., Brown, J.P. et al. Efficacy of lumiracoxib in osteoarthritis: A review of nine studies. J Int Med Res 2005, 33: 21-41.
59. Geusens, P., Alten, R., Rovensky, J. et al. Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis. Arthritis Rheum 2005, 52: 582-91.
60. Hartmann, S., Rordorf, C.M., Milosavljev, S. et al. Lumaricoxib dose not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. Ann Pharmacother 2004, 38: 1582-7.
61. Kalbag, J., Elder, C., Scott, G. et al. Concomitant administration of lumiracoxib and a triphasic oral contraceptive does not affect contraceptive activity or pharmacokinetic profile. J Clin Pharmacol 2004, 44: 646-54.